Research institute acquires Immune Tolerance Institute

Monday, June 13, 2011 09:45 AM

The David H. Murdock Research Institute (DHMRI) has acquired the Immune Tolerance Institute (ITI) as part of the North Carolina-based Institute’s mission to accelerate the discovery and development of breakthrough treatments for a range of immune-related diseases.

DHMRI provides integrated, state-of-the-art genomic, cellular, proteomic and bioinformatics technology platforms to both academic and industry partners undertaking both pre-clinical and clinical research.

By acquiring ITI, DHMRI will enhance its capabilities to accelerate the discovery of novel immunomodulatory therapies and of the corresponding biomarkers necessary for their effective translation into medical practice.

Biomarkers can help to better predict the course of disease progression and the likelihood of an individual's response to diet or therapeutic intervention, as well as serving as surrogate endpoints of mechanism, efficacy and safety.

"Advancing immune science will lead to new approaches to investigate the biological mechanisms of disease and functional properties of foods to better determine and predict the efficacy and safety of emerging products," said Mike Luther of the DHMRI. "The acquisition of ITI will allow us to extend the DHMRI's capabilities even further into the pre-clinical and clinical settings, ultimately improving the health of patients and consumers alike."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs